AMGN vs. EXAS: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at AMGN and EXAS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
AMGN’s market capitalization of 160.37 billion USD is substantially larger than EXAS’s 10.07 billion USD, indicating a significant difference in their market valuations.
EXAS carries a higher beta at 0.98, indicating it’s more sensitive to market moves, while AMGN (beta: 0.50) exhibits greater stability.
| Symbol | AMGN | EXAS |
|---|---|---|
| Company Name | Amgen Inc. | Exact Sciences Corporation |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Medical - Diagnostics & Research |
| CEO | Robert A. Bradway | Kevin T. Conroy |
| Price | 298.24 USD | 53.36 USD |
| Market Cap | 160.37 billion USD | 10.07 billion USD |
| Beta | 0.50 | 0.98 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | June 17, 1983 | February 1, 2001 |
| ADR | No | No |
Historical Performance
This chart compares the performance of AMGN and EXAS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
AMGN
92.94%
Drug Manufacturers - General Industry
- Max
- 95.59%
- Q3
- 76.92%
- Median
- 30.71%
- Q1
- 8.97%
- Min
- -14.85%
In the upper quartile for the Drug Manufacturers - General industry, AMGN’s Return on Equity of 92.94% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
EXAS
-36.42%
Medical - Diagnostics & Research Industry
- Max
- 57.35%
- Q3
- 18.17%
- Median
- 2.69%
- Q1
- -16.72%
- Min
- -48.78%
EXAS has a negative Return on Equity of -36.42%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Return on Invested Capital
AMGN
9.53%
Drug Manufacturers - General Industry
- Max
- 25.72%
- Q3
- 17.89%
- Median
- 11.47%
- Q1
- 9.39%
- Min
- 2.87%
AMGN’s Return on Invested Capital of 9.53% is in line with the norm for the Drug Manufacturers - General industry, reflecting a standard level of efficiency in generating profits from its capital base.
EXAS
-19.67%
Medical - Diagnostics & Research Industry
- Max
- 42.99%
- Q3
- 11.55%
- Median
- 3.02%
- Q1
- -11.49%
- Min
- -40.79%
EXAS has a negative Return on Invested Capital of -19.67%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.
Net Profit Margin
AMGN
17.39%
Drug Manufacturers - General Industry
- Max
- 34.51%
- Q3
- 23.04%
- Median
- 14.73%
- Q1
- 11.78%
- Min
- 2.18%
AMGN’s Net Profit Margin of 17.39% is aligned with the median group of its peers in the Drug Manufacturers - General industry. This indicates its ability to convert revenue into profit is typical for the sector.
EXAS
-36.06%
Medical - Diagnostics & Research Industry
- Max
- 22.76%
- Q3
- 15.19%
- Median
- 1.64%
- Q1
- -22.25%
- Min
- -78.24%
EXAS has a negative Net Profit Margin of -36.06%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin
AMGN
21.82%
Drug Manufacturers - General Industry
- Max
- 40.70%
- Q3
- 28.90%
- Median
- 23.41%
- Q1
- 19.05%
- Min
- 16.13%
AMGN’s Operating Profit Margin of 21.82% is around the midpoint for the Drug Manufacturers - General industry, indicating that its efficiency in managing core business operations is typical for the sector.
EXAS
-36.55%
Medical - Diagnostics & Research Industry
- Max
- 36.06%
- Q3
- 20.26%
- Median
- 6.15%
- Q1
- -21.89%
- Min
- -82.21%
EXAS has a negative Operating Profit Margin of -36.55%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | AMGN | EXAS |
|---|---|---|
| Return on Equity (TTM) | 92.94% | -36.42% |
| Return on Assets (TTM) | 6.64% | -17.86% |
| Return on Invested Capital (TTM) | 9.53% | -19.67% |
| Net Profit Margin (TTM) | 17.39% | -36.06% |
| Operating Profit Margin (TTM) | 21.82% | -36.55% |
| Gross Profit Margin (TTM) | 63.00% | 68.19% |
Financial Strength
Current Ratio
AMGN
1.17
Drug Manufacturers - General Industry
- Max
- 1.67
- Q3
- 1.37
- Median
- 1.26
- Q1
- 0.87
- Min
- 0.39
AMGN’s Current Ratio of 1.17 aligns with the median group of the Drug Manufacturers - General industry, indicating that its short-term liquidity is in line with its sector peers.
EXAS
2.73
Medical - Diagnostics & Research Industry
- Max
- 6.91
- Q3
- 4.11
- Median
- 2.46
- Q1
- 1.44
- Min
- 0.73
EXAS’s Current Ratio of 2.73 aligns with the median group of the Medical - Diagnostics & Research industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio
AMGN
9.24
Drug Manufacturers - General Industry
- Max
- 2.95
- Q3
- 2.44
- Median
- 0.86
- Q1
- 0.68
- Min
- 0.09
With a Debt-to-Equity Ratio of 9.24, AMGN operates with exceptionally high leverage compared to the Drug Manufacturers - General industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
EXAS
1.05
Medical - Diagnostics & Research Industry
- Max
- 1.10
- Q3
- 0.82
- Median
- 0.39
- Q1
- 0.21
- Min
- 0.01
EXAS’s leverage is in the upper quartile of the Medical - Diagnostics & Research industry, with a Debt-to-Equity Ratio of 1.05. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio
AMGN
3.19
Drug Manufacturers - General Industry
- Max
- 27.46
- Q3
- 14.40
- Median
- 7.80
- Q1
- 4.07
- Min
- 1.67
In the lower quartile for the Drug Manufacturers - General industry, AMGN’s Interest Coverage Ratio of 3.19 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.
EXAS
-57.46
Medical - Diagnostics & Research Industry
- Max
- 37.07
- Q3
- 5.62
- Median
- 1.76
- Q1
- -38.78
- Min
- -57.46
EXAS has a negative Interest Coverage Ratio of -57.46. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | AMGN | EXAS |
|---|---|---|
| Current Ratio (TTM) | 1.17 | 2.73 |
| Quick Ratio (TTM) | 0.88 | 2.38 |
| Debt-to-Equity Ratio (TTM) | 9.24 | 1.05 |
| Debt-to-Asset Ratio (TTM) | 0.64 | 0.44 |
| Net Debt-to-EBITDA Ratio (TTM) | 3.92 | -2.56 |
| Interest Coverage Ratio (TTM) | 3.19 | -57.46 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for AMGN and EXAS. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
AMGN
3.10%
Drug Manufacturers - General Industry
- Max
- 8.72%
- Q3
- 4.10%
- Median
- 3.34%
- Q1
- 1.89%
- Min
- 0.00%
AMGN’s Dividend Yield of 3.10% is consistent with its peers in the Drug Manufacturers - General industry, providing a dividend return that is standard for its sector.
EXAS
0.00%
Medical - Diagnostics & Research Industry
- Max
- 2.76%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
EXAS currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio
AMGN
82.64%
Drug Manufacturers - General Industry
- Max
- 266.46%
- Q3
- 78.91%
- Median
- 60.27%
- Q1
- 43.74%
- Min
- 0.00%
AMGN’s Dividend Payout Ratio of 82.64% is in the upper quartile for the Drug Manufacturers - General industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
EXAS
0.00%
Medical - Diagnostics & Research Industry
- Max
- 37.46%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
EXAS has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | AMGN | EXAS |
|---|---|---|
| Dividend Yield (TTM) | 3.10% | 0.00% |
| Dividend Payout Ratio (TTM) | 82.64% | 0.00% |
Valuation
Price-to-Earnings Ratio
AMGN
27.04
Drug Manufacturers - General Industry
- Max
- 27.96
- Q3
- 25.84
- Median
- 18.32
- Q1
- 16.65
- Min
- 3.39
A P/E Ratio of 27.04 places AMGN in the upper quartile for the Drug Manufacturers - General industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.
EXAS
-9.77
Medical - Diagnostics & Research Industry
- Max
- 48.28
- Q3
- 44.64
- Median
- 29.13
- Q1
- 22.34
- Min
- 15.59
EXAS has a negative P/E Ratio of -9.77. This occurs when a company has negative earnings (a net loss), making the ratio unsuitable for valuation analysis.
Forward P/E to Growth Ratio
AMGN
7.57
Drug Manufacturers - General Industry
- Max
- 3.10
- Q3
- 3.09
- Median
- 2.72
- Q1
- 2.18
- Min
- 1.02
AMGN’s Forward PEG Ratio of 7.57 is exceptionally high for the Drug Manufacturers - General industry. This suggests its stock price is very high relative to its expected earnings growth, signaling significant overvaluation risk.
EXAS
-9.07
Medical - Diagnostics & Research Industry
- Max
- 4.18
- Q3
- 3.64
- Median
- 2.40
- Q1
- 0.57
- Min
- 0.04
EXAS has a negative Forward PEG Ratio of -9.07. This typically results from negative earnings or forecasts of declining future earnings, making the ratio not meaningful for valuation.
Price-to-Sales Ratio
AMGN
4.70
Drug Manufacturers - General Industry
- Max
- 6.47
- Q3
- 4.47
- Median
- 3.53
- Q1
- 1.96
- Min
- 0.41
AMGN’s P/S Ratio of 4.70 is in the upper echelon for the Drug Manufacturers - General industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
EXAS
3.56
Medical - Diagnostics & Research Industry
- Max
- 12.53
- Q3
- 6.19
- Median
- 3.58
- Q1
- 1.95
- Min
- 0.58
EXAS’s P/S Ratio of 3.56 aligns with the market consensus for the Medical - Diagnostics & Research industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio
AMGN
25.85
Drug Manufacturers - General Industry
- Max
- 7.80
- Q3
- 7.80
- Median
- 5.30
- Q1
- 4.06
- Min
- 1.08
The P/B Ratio is often not a primary valuation metric for the Drug Manufacturers - General industry.
EXAS
4.16
Medical - Diagnostics & Research Industry
- Max
- 10.67
- Q3
- 5.74
- Median
- 2.95
- Q1
- 1.30
- Min
- 0.39
The P/B Ratio is often not a primary valuation metric for the Medical - Diagnostics & Research industry.
Valuation at a Glance
| Symbol | AMGN | EXAS |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 27.04 | -9.77 |
| Forward PEG Ratio (TTM) | 7.57 | -9.07 |
| Price-to-Sales Ratio (P/S, TTM) | 4.70 | 3.56 |
| Price-to-Book Ratio (P/B, TTM) | 25.85 | 4.16 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 14.69 | 51.85 |
| EV-to-EBITDA (TTM) | 16.88 | -14.42 |
| EV-to-Sales (TTM) | 6.12 | 4.33 |